DEEP EXPERIENCE. SHARED COMMITMENT.
"We take a private equity approach to a sector that’s traditionally been dominated by venture and early-stage growth firms. We'll work very closely with management to improve the operations of the business, update the product portfolio and revamp the commercial organization. We provide the support and resources our portfolio companies need to succeed.”
21
active portfolio companies
+
2000
employees worldwide
7
AP-II Investments to Date
9
successful exits
news
Apr 09, 2026
Click Therapeutics and Boehringer Ingelheim Announce Series D Investment and Funding to Advance Commercialization of CT-155
- The financing combines a $50M Series D investment by Boehringer Ingelheim with additional dedicated funding to support commercialization. As part of the agreement, Boehringer is transferring responsibility for commercializing CT-155 to Click Therapeutics.
- Granted Breakthrough Device Designation by the FDA in 2024,1 the CT-155 Phase III CONVOKE study was the first and only pivotal trial to show a statistically significant reduction in experiential negative symptoms of schizophrenia as an adjunct to standard of care antipsychotic treatment.2,3
- Treatment with CT-155 demonstrated a Cohen’s D effect size of -0.36 (p value= 0.0003) reflective of a 6.8-point improvement of negative symptoms severity as measured by CAINS-MAP at 16 weeks (vs. 4.2-point in digital control arm), representing a 62% relative improvement.2
- Click Therapeutics’ expertise in digital therapeutics, experience in the mental health space, and commitment to patient-centric approaches position the company well to bring this important therapy to patients.
Apr 09, 2026
Bioness Medical Acquires the Portable Neuromodulation Stimulator (PoNS®) SystemStrategic addition expands Bioness Medical’s platform into non-invasive central neuromodulation and strengthens leadership in neurorehabilitation
Aug 07, 2025
Boehringer and Click Therapeutics’ investigational prescription digital therapeutic CT-155 meets primary endpoint in CONVOKE study for negative symptoms in schizophrenia- CT-155 showed a reduction in experiential negative symptoms as an adjunct to standard of care antipsychotic therapy from baseline to week 16, as measured by CAINS-MAP.
- CT-155 is an investigational prescription digital therapeutic being evaluated to target negative symptoms of schizophrenia in a registrational randomized clinical trial.1,2
- Often underappreciated and less recognized, negative symptoms impact more than half of people living with schizophrenia.3
Jul 29, 2025
Axonius Acquires Medical Device Security Specialist Cynerio for More Than $100 Million to Target Healthcare MarketMove enables $2.6 billion cybersecurity unicorn to secure connected medical devices and protect patient care
Contact Us